Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!

Because patients with chronic myeloid leukemia in chronic phase live longer in the era of tyrosine kinase inhibitors, evaluating health‐related quality of life, especially by patient‐reported outcome measures, plays an important role in the management of their disease. Although more comparative data are still needed, this study demonstrated that olverembatinib therapy improved health‐related quality of life significantly over time in heavily treated patients with chronic myeloid leukemia.